Company: ARVN
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0001655759-25-000098
Chunk: 0

Company: ARVINAS, INC.
Filing Date: 2025-06-06
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On June 6, 2025, Arvinas, Inc. issued a press release announcing the submission of a New Drug Application to the U. S. Food and Drug Administration for vepdegestrant for the treatment of patients with estrogen receptor positive/human epidermal growth factor receptor 2-negative ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.